Tirzepatide: the complete evidence-based guide

Tirzepatide is the second-generation GLP-1-class drug that broke the weight-loss ceiling. By adding GIP-receptor activation to the GLP-1 pharmacology established by semaglutide, it produced roughly 50% greater weight loss in head-to-head trials — and became the fastest drug launch in pharmaceutical history along the way.

What tirzepatide is#

Tirzepatide is a synthetic 39-amino-acid peptide engineered to activate two receptors in the same molecule: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The structure is modified from a native GIP backbone with a C20 fatty-acid tail that binds albumin and extends the half-life to approximately five days — enabling once-weekly subcutaneous dosing.

GLP-1 agonism suppresses appetite, slows gastric emptying, and stimulates glucose-dependent insulin release. GIP agonism augments insulin secretion and has independent effects on adipose tissue. The combination produces larger average weight loss than either pathway alone — a finding confirmed across the Phase 3 SURMOUNT and SURPASS programmes.

The efficacy data#

Obesity: SURMOUNT-1. In SURMOUNT-1 (Jastreboff et al., NEJM 2022), tirzepatide 15 mg weekly produced 22.5% mean body-weight reduction at 72 weeks in adults with obesity. The 10 mg dose produced 21.4%. The 5 mg dose produced 16.0%. Placebo: 2.4%.

Obesity, head-to-head vs semaglutide: SURMOUNT-5. The NEJM head-to-head trial (2025) directly compared tirzepatide and semaglutide in obesity at their highest approved doses. Primary endpoint at 72 weeks: -20.2% with tirzepatide vs -13.7% with semaglutide. The waist-circumference effect was similarly separated: -18.4 cm vs -13.0 cm.

Type-2 diabetes: SURPASS programme. Across the SURPASS trials, tirzepatide consistently outperformed semaglutide, insulin degludec, and insulin glargine on HbA1c reduction. SURPASS-2 specifically compared tirzepatide 15 mg against semaglutide 1 mg weekly in adults with type-2 diabetes, and tirzepatide was superior across all doses tested.

Dosing and titration#

Tirzepatide dosing follows a strict escalation schedule to minimise gastrointestinal side effects:

Phase	Weekly dose	Duration
Start	2.5 mg	Weeks 1–4
Step 1	5 mg	Weeks 5–8
Step 2	7.5 mg	Weeks 9–12
Step 3	10 mg	Weeks 13–16
Step 4	12.5 mg	Weeks 17–20
Target	15 mg	Weeks 21+

Not every patient titrates to 15 mg. Many achieve clinically meaningful weight loss at 5 mg or 10 mg and stay there. The correct target dose is the lowest dose that produces the desired response with tolerable side effects. The Klarovel titration calculator builds a customised week-by-week schedule for a chosen target dose.

Reconstitution for research-grade vials: a typical 10 mg tirzepatide vial reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL. A 5 mg weekly dose equals 1 mL = 100 syringe units. The peptide calculator handles any vial size and target dose combination.

Side effects and tolerability#

Gastrointestinal events dominate the side-effect profile:

• Nausea (~29% of participants)
• Diarrhoea (~23%)
• Vomiting (~13%)
• Constipation (~17%)
• Decreased appetite (~12%)

Most are mild to moderate, dose-related, and concentrate during the escalation phase. Slower titration and adequate hydration mitigate intensity. Discontinuation rates due to adverse events run 6–7% in Phase 3 trials — lower than many oral diabetes medications.

Less common but meaningful signals:

• Hypoglycaemia when combined with insulin or sulfonylureas (class effect)
• Pancreatitis (class warning across GLP-1 drugs; incidence is low)
• Gallbladder disease (slightly elevated risk, class effect)
• Thyroid C-cell tumours observed in rodents; not confirmed in humans but informs the absolute contraindication for patients with personal or family history of medullary thyroid carcinoma or MEN 2

Regulatory status and access#

Tirzepatide is FDA-approved as:

• Mounjaro (2022) — adults with type-2 diabetes
• Zepbound (2023) — chronic weight management in adults with obesity or overweight with weight-related comorbidities

EMA-approved under the Mounjaro brand (type-2 diabetes and obesity). Approved and marketed in Norway via Legemiddelverket under the Mounjaro brand name; Zepbound is not separately distributed.

Insurance coverage and reimbursement status in Norway are evolving. As of April 2026, tirzepatide for obesity is generally not reimbursed under blue-resept (the Norwegian public reimbursement scheme) but may be prescribed on white resept at full out-of-pocket cost. For type-2 diabetes, reimbursement rules depend on individual clinical criteria.

Tirzepatide vs semaglutide vs retatrutide#

The receptor-count pattern across the class:

Drug	Receptors	Weight loss	Timepoint
Semaglutide 2.4 mg	GLP-1	14.9%	68 weeks
Tirzepatide 15 mg	GIP + GLP-1	22.5%	72 weeks
Retatrutide 12 mg	GIP + GLP-1 + glucagon	28.7%	68 weeks

Tirzepatide's position is as the FDA- and EMA-approved ceiling of the class. Semaglutide remains the first-line for most patients starting therapy. Retatrutide is still investigational and not expected to be available until 2027–2028.

For the full head-to-head comparison with semaglutide, see semaglutide vs tirzepatide.

Practical considerations#

Three things matter for anyone considering a tirzepatide protocol:

1. Titrate slowly. The gastrointestinal side-effect signal concentrates during dose escalation. Staying at each step for the full 4 weeks before increasing reduces the risk of intolerable nausea. The titration calculator builds the schedule.
2. Bloodwork before and during. HbA1c, lipid panel, and TSH are minimum baseline. Repeat at 12 and 24 weeks to confirm metabolic response and screen for thyroid changes.
3. Klarovel's catalogue stocks tirzepatide research product in pen formats (12 mg and 40 mg). For protocol planning, the intake questionnaire screens for contraindications and the peptide calculator handles the dose math.

Tirzepatide is the most important incremental step the GLP-1 class has made since semaglutide. For a well-screened, well-titrated patient, the efficacy is real and the side-effect profile is manageable. The rest is discipline on the escalation schedule and honesty about the data.